Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurelis has concluded patient dosing in a Phase I trial evaluating diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.
Subscribe to our email newsletter
Through the collaboration with University of Minnesota and James Cloyd, Neurelis has also partnered with experts in clinical research of the nasal delivery of benzodiazepines.
The company expects to reveal the trial results in June.
Neurelis chairman David Hale said the company has incorporated proprietary technologies to develop intranasal diazepam formulations that can be delivered with a standard sprayer to patients experiencing acute breakthrough seizures.
"These intranasal product formulations seek to address the need for a convenient and effective therapy that could help reduce acute breakthrough seizures and avoid the need for costly emergency room visits," Hale said.